Peter Dudek
Präsident bei Merck Research Ventures
Profil
Peter Dudek has over 15 years of experience in the life sciences industry spanning research, company building, corporate and traditional venture, across a broad range of therapeutic areas and modalities.
He currently serves as President and Managing Partner of MRL Ventures (MRLV) Fund and is responsible for its investments in Ambagon Therapeutics, Caraway Therapeutics, InduPro Labs, Mozart Therapeutics, Photys Therapeutics and Tallac Therapeutics.
Past board involvements include Carisma Therapeutics (NASDAQ: CARM), Hotspot Therapeutics, Imago Biosciences (acquired by Merck & Co., Inc., Rahway, NJ), Kymera Therapeutics (NASDAQ: KYMR), Lava Therapeutics (NASDAQ: LAVA), LifeMine Therapeutics, Tidal Therapeutics (acquired by Sanofi) and Xilio Therapeutics (NASDAQ: XLO).
Prior to MRLV, he was a Principal with Wellington Partners, a European venture fund with more than $1B under management.
He has held roles at Entrepreneurs Fund and at the corporate venture arm of Novartis.
Dr. Dudek received his B.Sc.
with Honors from the University of British Columbia and was a research associate at the BC Centre for Disease Control.
He obtained his Ph.D.
from the University of Geneva and was a Postdoctoral Fellow at the University of Oxford.
Aktive Positionen von Peter Dudek
Unternehmen | Position | Beginn |
---|---|---|
Merck Research Ventures
Merck Research Ventures Investment ManagersFinance Merck Research Ventures, a subsidiary of Merck Research Laboratories is a venture capital firm founded in 2000. The firm is headquartered in Boston, Massachusetts. | Präsident | 01.03.2021 |
Ambagon Therapeutics, Inc.
Ambagon Therapeutics, Inc. BiotechnologyHealth Technology Ambagon Therapeutics, Inc. provides healthcare services. It specializes in biotechnology. The company is headquartered in San Francisco, CA. | Direktor/Vorstandsmitglied | 01.07.2020 |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | Direktor/Vorstandsmitglied | 01.12.2020 |
InduPro, Inc.
InduPro, Inc. BiotechnologyHealth Technology InduPro, Inc. engages in integrating inherent protein proximity at the cell surface and translates biological insights into transformative therapeutics. The company is based in San Francisco, CA. The company was founded by K. Christopher Garcia. | Direktor/Vorstandsmitglied | 01.02.2022 |
Caraway Therapeutics, Inc.
Caraway Therapeutics, Inc. BiotechnologyHealth Technology Caraway Therapeutics, Inc. provides heathcare services. The company was founded by Timothy Harris, Wade Harper ,Ivan Dikic ,Tony Hyman and is headquartered in Cambridge, MA. | Direktor/Vorstandsmitglied | 01.11.2021 |
Tallac Therapeutics, Inc.
Tallac Therapeutics, Inc. BiotechnologyHealth Technology Tallac Therapeutics, Inc. engages in the development of immunomodulating polynucleotides. The company is headquartered in Burlingame, CA. | Direktor/Vorstandsmitglied | 01.11.2021 |
Ehemalige bekannte Positionen von Peter Dudek
Unternehmen | Position | Ende |
---|---|---|
Xilio Therapeutics LLC
Xilio Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Xilio Therapeutics, Inc., Xilio Therapeutics LLC develops cancer biopharmaceuticals. The company is based in Waltham, MA. The CEO of the company is René Russo. | Direktor/Vorstandsmitglied | 01.02.2021 |
Wellington Partners GmbH
Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | Private Equity Investor | 31.03.2018 |
Entrepreneurs Fund Management LLP
Entrepreneurs Fund Management LLP Investment ManagersFinance Entrepreneurs Fund Management LLP (Entrepreneurs Fund) is a venture capital subsidiary of Bellefontaine Investments AG founded in 2002. The firm is headquartered in London, the United kingdom. | Private-Equity-Analyst | 01.01.2016 |
Ausbildung von Peter Dudek
University of British Columbia | Undergraduate Degree |
University of Geneva | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 9 |
---|---|
Entrepreneurs Fund Management LLP
Entrepreneurs Fund Management LLP Investment ManagersFinance Entrepreneurs Fund Management LLP (Entrepreneurs Fund) is a venture capital subsidiary of Bellefontaine Investments AG founded in 2002. The firm is headquartered in London, the United kingdom. | Finance |
Wellington Partners GmbH
Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | Finance |
Merck Research Ventures
Merck Research Ventures Investment ManagersFinance Merck Research Ventures, a subsidiary of Merck Research Laboratories is a venture capital firm founded in 2000. The firm is headquartered in Boston, Massachusetts. | Finance |
Ambagon Therapeutics, Inc.
Ambagon Therapeutics, Inc. BiotechnologyHealth Technology Ambagon Therapeutics, Inc. provides healthcare services. It specializes in biotechnology. The company is headquartered in San Francisco, CA. | Health Technology |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | Health Technology |
Xilio Therapeutics LLC
Xilio Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Xilio Therapeutics, Inc., Xilio Therapeutics LLC develops cancer biopharmaceuticals. The company is based in Waltham, MA. The CEO of the company is René Russo. | Health Technology |
InduPro, Inc.
InduPro, Inc. BiotechnologyHealth Technology InduPro, Inc. engages in integrating inherent protein proximity at the cell surface and translates biological insights into transformative therapeutics. The company is based in San Francisco, CA. The company was founded by K. Christopher Garcia. | Health Technology |
Caraway Therapeutics, Inc.
Caraway Therapeutics, Inc. BiotechnologyHealth Technology Caraway Therapeutics, Inc. provides heathcare services. The company was founded by Timothy Harris, Wade Harper ,Ivan Dikic ,Tony Hyman and is headquartered in Cambridge, MA. | Health Technology |
Tallac Therapeutics, Inc.
Tallac Therapeutics, Inc. BiotechnologyHealth Technology Tallac Therapeutics, Inc. engages in the development of immunomodulating polynucleotides. The company is headquartered in Burlingame, CA. | Health Technology |